What is Geron's market cap?

Geron (GERN) has a market capitalization of $949.5M and trades on NASDAQ.

What is Geron's revenue and profitability?

Geron generated $187.7M in trailing twelve-month revenue with a net loss of $67.3M, representing a net margin of -682.5%. These figures are based on the Q1 2026 filing.

Who are Geron's competitors?

Geron's key competitors include Incyte, Bristol-Myers Squibb, Keros Therapeutics, Inc. Common Stock, and others. These companies compete in similar markets and product categories.

Who does Geron partner with?

Geron's notable partners include Tanner Pharma, Bristol-Myers Squibb.

Where is Geron headquartered?

Geron is headquartered in United States of America and employs approximately 141 people. It has been publicly traded since 1996.

Geron

GERN

Geron is a commercial-stage biopharmaceutical company focused on developing and commercializing first-in-class telomerase inhibitors for blood cancers.

Market cap

$949.45M+35.5%

Revenue$187.7M+537%

Net income-$67.3M+51.6%

EPS (diluted)-$0.11+47.6%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 6, 2026

Revenue$51.8MBeat by $1.2M EPS-$0.01Beat by $0.02

Read the full report

Next report

Aug 5, 2026 (In 1 week)

Revenue estimate$55.3M

EPS estimate-$0.01

Financials

Q1 2026

Income statement

See full

Revenue$51.8M+30.9%

Operating income$158.0K+101%

Net income-$3.6M+81.6%

EPS (diluted)-$0.01+66.7%

Balance sheet

See full

Cash & equivalents$48.7M-12.2%

Total debt$134.0M+10.0%

Total equity$229.1M-14.6%

Total assets$534.1M-5.0%

Cash flow

See full

Operating cash flow-$62.9M-31.1%

Valuation & ratios

Valuation

See full

Market cap$949.45M+35.5%

Enterprise value$1.03B+24.9%

P/S5.1×—

Returns & leverage

See full

Return on equity-27.1%-7.8pp

Debt / equity0.6×+0.1×

Current ratio6.8×-1.1×

Segments

By product

See full

Gross product revenue$65.4M+44.2%

Sales returns and allowances-$1.6M-1,308%

Government rebates-$1.7M-2,412%

Distributor service fees-$2.2M—

Chargebacks-$8.2M—

By segment

See full

Reportable Segment$51.8M+30.8%

Competitors

By market cap

Bristol-Myers Squibb$127.75B+32.1%

Incyte$23.7B+74.9%

Immunome$2.6B+171%

Geron$949.5M+29.6%

Lyell Immunopharma, Inc.$317.6M+24.5%

Immuneering Corporation$282.1M+100%

Keros Therapeutics$202.1M-65.7%

GT Biopharma$12.0M+75.3%

By revenue growth

Geron+537%

Incyte+26.9%

Bristol-Myers Squibb+1.8%

Immunome-63.3%

By net margin

Incyte27.71%+8.7pp

Bristol-Myers Squibb15.01%+3.8pp

Geron-682.47%+436pp

Immunome-5,593.85%-3,719pp

Profile

Geron is a commercial-stage biopharmaceutical company focused on developing and commercializing first-in-class telomerase inhibitors for blood cancers. Its lead product, RYTELO, utilizes Nobel Prize-winning science to inhibit the proliferation of malignant cells in hematologic malignancies. The company aims to modify the underlying course of disease in patients with high unmet clinical needs.

Competitive position

Geron holds a first-in-class position as the provider of the only approved telomerase inhibitor for lower-risk MDS.

GeographiesUnited States, European Union, Iceland, Norway, Liechtenstein

Customer segmentsAdult patients with lower-risk MDS, Relapsed/refractory myelofibrosis patients

Business modelDirect Product Sales, Research and Development

SuppliersSpecialized chemical manufacturers, Contract manufacturing organizations, Clinical research organizations

CustomersSpecialty distributors, Healthcare providers, Government and private payors

CountryUnited States of America

Listed1996

Employees141.0

CEOHarout Semerjian

SectorHealthcare

IndustryBiotechnology

Websitegeron.com

FilingsSEC EDGAR

Ask your AI about Geron.

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Geron's market cap?: Geron (GERN) has a market capitalization of $949.5M and trades on NASDAQ.
What is Geron's revenue and profitability?: Geron generated $187.7M in trailing twelve-month revenue with a net loss of $67.3M, representing a net margin of -682.5%. These figures are based on the Q1 2026 filing.
Who are Geron's competitors?: Geron's key competitors include Incyte, Bristol-Myers Squibb, Keros Therapeutics, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
Who does Geron partner with?: Geron's notable partners include Tanner Pharma, Bristol-Myers Squibb.
Where is Geron headquartered?: Geron is headquartered in United States of America and employs approximately 141 people. It has been publicly traded since 1996.